[go: up one dir, main page]

DK2493474T3 - Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler - Google Patents

Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler Download PDF

Info

Publication number
DK2493474T3
DK2493474T3 DK10827530.6T DK10827530T DK2493474T3 DK 2493474 T3 DK2493474 T3 DK 2493474T3 DK 10827530 T DK10827530 T DK 10827530T DK 2493474 T3 DK2493474 T3 DK 2493474T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
medicinal products
continuous delivery
delivery
Prior art date
Application number
DK10827530.6T
Other languages
English (en)
Inventor
Padma Nanduri
T Aaron Dyer
Original Assignee
Intratus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intratus Inc filed Critical Intratus Inc
Application granted granted Critical
Publication of DK2493474T3 publication Critical patent/DK2493474T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
DK10827530.6T 2009-10-30 2010-10-29 Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler DK2493474T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25661409P 2009-10-30 2009-10-30
US28947109P 2009-12-23 2009-12-23
PCT/US2010/054736 WO2011053792A2 (en) 2009-10-30 2010-10-29 Methods and compositions for sustained delivery of drugs

Publications (1)

Publication Number Publication Date
DK2493474T3 true DK2493474T3 (da) 2019-10-14

Family

ID=43923004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10827530.6T DK2493474T3 (da) 2009-10-30 2010-10-29 Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler

Country Status (14)

Country Link
US (3) US20110104083A1 (da)
EP (3) EP3569223A1 (da)
CY (1) CY1122417T1 (da)
DK (1) DK2493474T3 (da)
ES (1) ES2752008T3 (da)
HR (1) HRP20191828T1 (da)
HU (1) HUE046071T2 (da)
LT (1) LT2493474T (da)
PL (1) PL2493474T3 (da)
PT (1) PT2493474T (da)
RS (1) RS59483B1 (da)
SI (1) SI2493474T1 (da)
SM (1) SMT201900633T1 (da)
WO (2) WO2011053792A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3569223A1 (en) * 2009-10-30 2019-11-20 Intratus, Inc. Methods and compositions for sustained delivery of drugs
AU2011231543B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US20140142055A1 (en) * 2011-06-29 2014-05-22 Insite Vision Corporation Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US20130045269A1 (en) * 2011-08-18 2013-02-21 Sorush LLC Formulations and methods for wound treatment
US20130251783A1 (en) * 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
AU2012324543B2 (en) 2011-10-19 2017-08-10 Galderma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
WO2013169315A1 (en) * 2012-05-09 2013-11-14 Hill David W Method for treating macular degeneration
KR20150136077A (ko) 2013-03-10 2015-12-04 페리테크 파마 엘티디. 국소 조성물 및 국소 질환의 치료 방법
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US20140303166A1 (en) * 2013-04-08 2014-10-09 Gordon C. Tang Cosmetic method for changing the appearance of eyes
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3096721A4 (en) * 2014-01-22 2017-10-18 Marcio Marc Abreu Devices configured to provide treatment at an abreu brain thermal tunnel
DE202014010412U1 (de) * 2014-02-21 2015-09-01 Ursapharm Arzneimittel Gmbh Mikro- oder Nanoemulsion zur ophthalmologischen Anwendung
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US20180015166A1 (en) * 2015-02-02 2018-01-18 Santen Pharmaceutical Co., Ltd Polyaphrons and palpebral administration thereof
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CA2952818A1 (en) * 2015-05-01 2016-11-10 Eran Eilat Compositions for the treatment of epistaxis
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
EP3313413B1 (en) * 2015-09-28 2024-12-04 Azura Ophthalmics Ltd Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US10286035B2 (en) 2015-10-14 2019-05-14 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US11040062B2 (en) 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
JP7014797B2 (ja) 2016-12-23 2022-02-01 カレオ，インコーポレイテッド 乳児及び子供に薬物を送達するための薬物送達装置及び方法
CN106963706A (zh) * 2017-03-17 2017-07-21 广州欧慕生物科技有限公司 一种眼部护理组合物及包含该组合物的药品和眼部护理品
MX2019011697A (es) * 2017-03-29 2020-02-12 Azura Ophthalmics Ltd Agentes para aumentar la secrecion de lipidos en la glandula de meibomio.
USD841152S1 (en) 2017-06-27 2019-02-19 Monica S. Naylor Eye drop container
JP2021501803A (ja) * 2017-11-03 2021-01-21 ブリエン ホールデン ビジョン インスティチュート リミテッド 近視の進行を制御し且つ／又は減少させるための医薬組成物
CN111372564B (zh) 2017-11-21 2024-10-15 创盛桥康制药有限公司 用于治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US10695351B2 (en) * 2018-07-30 2020-06-30 Harrow Ip, Llc Pharmaceutical formulations for the treatment of dry eye and methods for fabricating and using thereof
CN111212642A (zh) * 2018-08-29 2020-05-29 奥古根有限公司 眼用组合物及使用方法
US20210338141A1 (en) * 2018-09-07 2021-11-04 Korwave, Llc Seizure detection system in mobile subjects
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
AU2020320222A1 (en) * 2019-08-01 2022-03-03 Gennova Biopharmaceuticals Limited Opthalmic composition of Bevacizumab
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
KR20230042077A (ko) 2020-09-11 2023-03-27 인트라투스-네바다, 인크. 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations
TW202329958A (zh) * 2022-01-25 2023-08-01 張金明 西維美林水溶液組合物和使用方法
EP4511001A1 (en) 2022-04-21 2025-02-26 Glaukos Corporation Ophthalmic topical cream compositions
EP4525826A1 (en) 2022-05-18 2025-03-26 Glaukos Corporation Novel applications of zwitterions in ophthalmic topical cream compositions and preparations
WO2024258300A1 (en) * 2023-06-13 2024-12-19 Gosiengfiao David Harold Method of enhancing the systemic hypoglycemic effect of topically applied insulin with the use of prostaglandin analogues: a novel fixed combination eye drop formulation of insulin and prostaglandin analogue for the lowering of blood glucose level

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2703777A (en) * 1950-05-02 1955-03-08 Iso Sol Company Inc Ophthalmological preparations and vehicles and method of making the same
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
SE8701258D0 (sv) * 1987-03-26 1987-03-26 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5278142A (en) * 1989-03-20 1994-01-11 Orbon Corporation Systemic delivery of polypeptides through the eye
JPH0551568A (ja) 1991-08-27 1993-03-02 Sekisui Chem Co Ltd アクリル系ホツトメルト接着剤組成物
JPH07228532A (ja) 1993-04-22 1995-08-29 Senju Pharmaceut Co Ltd 水性液剤、その有効成分の溶解性向上方法および安定化方法
JP3066561B2 (ja) 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
WO1998030900A2 (en) * 1997-01-06 1998-07-16 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
JP4489851B2 (ja) 1997-02-04 2010-06-23 千寿製薬株式会社 アリールカルボン酸の安定化方法、その安定化剤および安定化されたアリールカルボン酸からなる水性液剤
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
JP4591728B2 (ja) 1998-12-28 2010-12-01 大正製薬株式会社 眼精疲労改善用点眼剤
EE200100500A (et) * 1999-03-26 2003-02-17 Pozen Inc. Suure võimsusega dihüdroergotamiini kompositsioonid
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
JP2001302518A (ja) * 2000-02-15 2001-10-31 Rohto Pharmaceut Co Ltd 官能改善方法および官能改善剤
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
EP1386611A4 (en) * 2001-04-19 2009-05-13 Teika Pharmaceutical Co Ltd MEDICAL DEVICES AND MEDICAL SETS
JP2003055225A (ja) 2001-08-16 2003-02-26 Rohto Pharmaceut Co Ltd 安定化された組成物
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
JP4629578B2 (ja) * 2003-01-22 2011-02-09 ニチバン株式会社 眼疾患治療用経皮吸収型製剤
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
EP1754491B1 (en) * 2004-05-21 2010-03-03 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
US20100160293A1 (en) * 2005-02-17 2010-06-24 Kakuji Tojo Solid Ophthalmic Drug for External Use
JP2008533171A (ja) * 2005-03-18 2008-08-21 ニトロメッド インコーポレーティッド アンギオテンシン変換酵素阻害剤の有機酸化窒素増強塩、組成物および使用法
US20060275232A1 (en) * 2005-06-01 2006-12-07 L'oreal Two-composition product, uses thereof, and makeup kit containing this product
US7381707B2 (en) * 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
JP5315051B2 (ja) * 2005-07-08 2013-10-16 千寿製薬株式会社 オロパタジンを含む眼科用経皮吸収型製剤
US20090143359A1 (en) * 2005-07-08 2009-06-04 Akiharu Isowaki Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine
JPWO2007013661A1 (ja) * 2005-07-26 2009-02-12 千寿製薬株式会社 眼科用経皮吸収型製剤
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
US20080020064A1 (en) * 2006-07-21 2008-01-24 Advanced Vision Research Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
WO2008026756A1 (en) 2006-08-28 2008-03-06 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneous absorption type preparation
CA2679448A1 (en) * 2007-02-28 2008-09-04 Aciex, Inc. Methods and compositions for normalizing meibomian gland secretions
EP3167886B1 (en) * 2007-10-19 2020-08-05 Novartis AG Compositions and methods for treatment of macular edema
KR20100099145A (ko) * 2007-10-31 2010-09-10 파멜라 립킨 프로스타글란딘 유사체 조성물 및 상피 관련 질환을 치료하는 방법
EP3569223A1 (en) * 2009-10-30 2019-11-20 Intratus, Inc. Methods and compositions for sustained delivery of drugs

Also Published As

Publication number Publication date
HRP20191828T1 (hr) 2019-12-27
LT2493474T (lt) 2019-10-10
WO2011053792A3 (en) 2011-09-22
PT2493474T (pt) 2019-11-26
EP2493474A4 (en) 2014-04-23
EP2493474B1 (en) 2019-09-04
EP2493475A2 (en) 2012-09-05
EP3569223A1 (en) 2019-11-20
WO2011053801A3 (en) 2011-09-29
SI2493474T1 (sl) 2019-11-29
PL2493474T3 (pl) 2020-03-31
CY1122417T1 (el) 2021-01-27
SMT201900633T1 (it) 2020-01-14
US20110104206A1 (en) 2011-05-05
WO2011053792A4 (en) 2011-11-24
WO2011053801A4 (en) 2011-11-10
ES2752008T3 (es) 2020-04-02
WO2011053792A2 (en) 2011-05-05
EP2493474A2 (en) 2012-09-05
RS59483B1 (sr) 2019-12-31
US20110104083A1 (en) 2011-05-05
US9034830B2 (en) 2015-05-19
US20150174211A1 (en) 2015-06-25
EP2493475A4 (en) 2014-10-29
WO2011053801A2 (en) 2011-05-05
HUE046071T2 (hu) 2020-01-28

Similar Documents

Publication Publication Date Title
DK2493474T3 (da) Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
DK2419670T3 (da) Leveringsmetode og sammensætninger
DK3626258T3 (da) Fremgangsmåder og sammensætninger til cns-levering af iduronat-2-sulfatase
ZA201107699B (en) Stable pharmaceutical composition and methods of using same
DK3378862T3 (da) Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
DK3527241T3 (da) Indretning til administration af lægemiddel
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
DK3202460T3 (da) Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme
IL216374A0 (en) Compositions and methods for drug delivery
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
DK2482881T3 (da) Mekanisme til indretning til indlevering af lægemiddel
DK2588097T3 (da) Farmaceutiske sammensætninger omfattende paracetamol og fremgangsmåde til fremstilling af samme
DK2482799T3 (da) Farmaceutiske aerosolformuleringer af formoterol og beclometasondipropionat
IL219018A (en) Radzolid Pharmaceuticals and Uses
DK2266596T3 (da) Farmaceutisk sammensætning og fremgangsmåde til fremstilling deraf
HU0900698D0 (en) Pharmaceutical compositions of enhanced stability